- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02384629
PCI With AXXESS Biolimus A9 Eluting Bifurcation Stent in Treating Coronary Artery Bifurcation Disease
July 26, 2016 updated by: Yonsei University
- To compare the safety and efficacy of AXXESS stent with conventional DES in patients with coronary artery bifurcation disease
- To assess the impact of optical coherence tomography (OCT) guidance on clinical outcomes following the stent type
Study Overview
Status
Withdrawn
Conditions
Study Type
Interventional
Phase
- Phase 4
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Provision of informed consent prior to any study specific procedures,
- Patients ≥ 19 years old,
- Patients who are expected to undergo PCI for bifurcation lesions.
Exclusion Criteria:
- Age> 85 years,
- Cardiogenic shock or unstable patients,
- Increased risk of bleeding, anemia, thrombocytopenia,
- A need for oral anticoagulation therapy,
- Pregnant women or women with potential childbearing,
- Life expectancy < 1 year.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: AXXESS stent1
AXXESS stent (OCT-guided)
|
The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer.
It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation.
Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities.
With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
|
EXPERIMENTAL: Conventional DES1
Conventional DES (Biomatrix flex stent, OCT-guided)
|
BioMatrix Flex is abluminal biodegradable polymer DES.
Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS.
It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design.
Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities.
With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
|
ACTIVE_COMPARATOR: AXXESS stent2
AXXESS stent (Angio-guided)
|
The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer.
It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation.
We use the conventional coronary angiography.
|
ACTIVE_COMPARATOR: Conventional DES2
Conventional DES (Biomatrix flex stent, Angio-guided)
|
BioMatrix Flex is abluminal biodegradable polymer DES.
Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS.
It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design.
We use the conventional coronary angiography.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Late loss of side branch(SB)
Time Frame: 9 months after procedure
|
Late loss was defined as the difference between the minimal luminal diameter (MLD) immediately after the procedure and the MLD at 9-month follow-up, Measured the change in MLD by Quantitative coronary angiography (QCA)
|
9 months after procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cardiovascular (CV) death
Time Frame: 9 months after procedure
|
death for CV cause (MI, stroke)
|
9 months after procedure
|
Myocardial infarction (MI)
Time Frame: 9 months after procedure
|
MI definition: rise of cardiac biomarker with at least one of the following: Symptoms of ischemia, New or presumed new significant ST-segment-T wave (ST-T) changes or new left bundle branch block (LBBB), Development of pathological Q waves in the ECG, Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality, identification of an intracoronary thrombus by angiography or autopsy
|
9 months after procedure
|
stent thrombosis (ST)
Time Frame: 9 months after procedure
|
ST definition: Academic Research Consortium (ARC) definition
|
9 months after procedure
|
SB closure
Time Frame: 9 months after procedure
|
SB closure: TIMI flow < 3 and/or stenosis >75%
|
9 months after procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2015
Primary Completion (ANTICIPATED)
March 1, 2017
Study Completion (ANTICIPATED)
December 1, 2017
Study Registration Dates
First Submitted
March 4, 2015
First Submitted That Met QC Criteria
March 4, 2015
First Posted (ESTIMATE)
March 10, 2015
Study Record Updates
Last Update Posted (ESTIMATE)
July 27, 2016
Last Update Submitted That Met QC Criteria
July 26, 2016
Last Verified
July 1, 2016
More Information
Terms related to this study
Other Study ID Numbers
- 1-2014-0079
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Bifurcation Lesions
-
Nova-Med Medical Research AssociationCompletedCoronary Bifurcation Lesions
-
Krankenhaus HetzelstiftCompleted
-
Acotec Scientific Co., LtdShanghai Zhongshan HospitalRecruitingCoronary Bifurcation LesionsChina
-
Nanjing First Hospital, Nanjing Medical UniversityCompletedCoronary Bifurcation LesionsChina
-
Universitaire Ziekenhuizen KU LeuvenBiosensors InternationalUnknownTrue Coronary Bifurcation LesionsBelgium
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Recruiting
-
Minneapolis Heart Institute FoundationRecruitingCoronary Artery Disease | Coronary Bifurcation LesionsUnited States
-
Hyeon-Cheol GwonCompletedCoronary Bifurcation LesionKorea, Republic of
-
J.J. WykrzykowskaAbbott Medical DevicesUnknownMyocardial Infarction | Infarction | Ischemia | Myocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Arteriosclerosis | Coronary Bifurcation Lesions | Arterial Occlusive LesionsNetherlands
Clinical Trials on OCT-guided PCI with AXXESS stent
-
Chonnam National University HospitalAbbott Medical DevicesRecruitingCoronary Artery Disease | Angina PectorisKorea, Republic of
-
Odense University HospitalActive, not recruitingMyocardial Infarction | Coronary Artery DiseaseDenmark
-
Catholic University of the Sacred HeartUnknownIschemic Heart DiseaseItaly
-
Yonsei UniversityCompletedCoronary Artery DiseaseKorea, Republic of
-
University Hospital Inselspital, BerneTerminated
-
Aarhus University Hospital SkejbyAbbottActive, not recruitingIschemic Heart Disease | Ischaemic Heart DiseaseDenmark, United Kingdom, Sweden, Finland, Germany, Belgium, Norway, Poland, Netherlands, Estonia, Ireland, Italy, Latvia
-
Careggi HospitalCompletedCoronary Artery | Stent Thrombosis | Platelet | ThrombusItaly
-
Assiut UniversityWakayama Medical UniversityCompleted
-
Harbin Medical UniversityNot yet recruitingIntravascular Imaging and Microvascular Obstruction
-
Abbott Medical DevicesAbbottCompletedCoronary Artery Disease | Atherosclerosis | Coronary Stenosis | STEMI | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial InfarctionUnited States, Spain, Australia, United Kingdom, Canada, New Zealand, Denmark, Switzerland, Germany, Netherlands, India, Japan, Italy, Belgium, France, Hong Kong, Portugal, Singapore, Sweden, Taiwan